nafamostat has been researched along with Buerger Disease in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Urabe, Y | 1 |
| Ideishi, M | 1 |
| Sasaguri, M | 1 |
| Ikeda, M | 1 |
| Arakawa, K | 1 |
1 trial available for nafamostat and Buerger Disease
| Article | Year |
|---|---|
Beneficial effects of a serine protease inhibitor in peripheral vascular disease.
Topics: Aged; Arteriosclerosis Obliterans; Benzamidines; Chronic Disease; Exercise Test; Female; Femoral Vei | 1993 |